Laboratory or Test Result

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

1 week ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Isomorphic Labs Secures $600M to Accelerate AI-Powered Drug Discovery

3 weeks ago talkbio0Tagged Antibodies, Aortic Valve Insufficiency, Demis, expansion, Hassabis, Isomorphous, Laboratory test finding, U.S.

AI drug discovery, Isomorphic Labs, Demis Hassabis, funding round, antibodies, US expansion

Isomorphic Labs raises $600M to push AI-designed drugs into clinic

3 weeks ago talkbio0Tagged AI-designed, development aspects, Isomorphous, Laboratory test finding

Isomorphous, Laboratory test finding, development aspects, AI-designed

Lila Sciences Emerges with $200M to Build AI-Powered Scientific Superintelligence Platform

1 month ago talkbio0Tagged Aortic Valve Insufficiency, autonomous, Flagship, Laboratory test finding, Pioneering, Plant seeds, scientific discovery

AI, scientific discovery, autonomous labs, Flagship Pioneering, seed funding

Leyden Labs Secures $70 Million Funding to Develop Broad Protection Against Respiratory Viruses

3 months ago talkbio0Tagged biotech, Laboratory test finding, Leyden, Mucosal Protection Platform, Nasal, Nasal defenses, PanFlu, Protection, Respiratory viruses

Leyden Labs, Respiratory viruses, Influenza, Nasal defenses, Broad protection, PanFlu, Mucosal Protection Platform, Biotech funding

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

4 months ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

4 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%

7 months ago talkbio0Tagged Antibodies, CD47 Antigen, Inflammatory Bowel Diseases, Laboratory test finding, Programs - Publication Format, Shattuck, SL 325, TNFRSF25 gene

Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults

1 year ago talkbio0Tagged Anemia, Approved, Black Box Warning, Chronic Kidney Diseases, Daprodustat, Effectiveness, Hemoglobin concentration result, Jesduvroq, Oral Medication, post-marketing safety, Safety, United States Food and Drug Administration, vadadustat, Vafseo

Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data